-

06:16:21 AM

LPCN Stock News

LPCN - Lipocine Inc

05/06/21 8:00 AM

Nasdaq : LPCN

earnings

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2021

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the first quarter ended March 31, 2021 and provided a corporate update.First Quarter Recent

RHEA-AI

neutral

03/11/21 8:00 AM

Nasdaq : LPCN

earnings

Lipocine Announces Financial Results For The Year Ended December 31, 2020

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the fourth quarter and year ended December 31, 2020, and provided a corporate

RHEA-AI

positive

03/11/21 8:00 AM

Nasdaq : LPCN

conferences

Lipocine To Present At M Vest / Maxim Conference And At The Lytham Partners Conference

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the M Vest LLC and Maxim Group LLC Emerging Growth Virtual Conference and the Lytham

RHEA-AI

neutral

03/04/21 8:00 AM

Nasdaq : LPCN

Lipocine Announces Publication in Journal of Endocrinological Investigation Highlighting the Potential of LPCN 1144 in the Treatment of NASH and Hepatic Fibrosis

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the publication of preclinical results supporting the therapeutic potential of LPCN 1144 in the treatment of and

RHEA-AI

neutral

03/03/21 8:00 AM

Nasdaq : LPCN

Lipocine Announces Presentations on TLANDO™ at ENDO 2021 Conference

Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data for lead candidate TLANDO™ will be presented at the ENDO 2021 Conference, to take place March

RHEA-AI

neutral

02/26/21 8:00 AM

Nasdaq : LPCN

conferences

Lipocine to Present at Two Upcoming Investor Conferences

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Raymond James 42 nd Annual Institutional Investors Conference and the H.C.

RHEA-AI

neutral

01/28/21 4:00 PM

Nasdaq : LPCN

offering

Lipocine Closes Underwritten Public Offering Of Common Stock

Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the closing of an underwritten public offering of 16,428,571 shares of its common stock, offered at a price of $1.75 to

RHEA-AI

neutral

01/26/21 9:00 AM

Nasdaq : LPCN

offering

Lipocine Prices $25 Million Underwritten Public Offering Of Common Stock

Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the pricing of an underwritten public offering of 14,285,714 shares of its common stock, offered at a price of $1.75 to

RHEA-AI

neutral

01/25/21 4:00 PM

Nasdaq : LPCN

offering

Lipocine Announces Launch Of Public Offering Of Common Stock

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, the

RHEA-AI

neutral

01/14/21 8:00 AM

Nasdaq : LPCN

Lipocine Announces USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Patent Trial and Appeal Board ("PTAB") of the United States Patent and Trademark Office ("USPTO") declared

RHEA-AI

neutral

Prev 1 2 3 4 5 6 Next

LPCN Data

Websitewww.lipocine.com
CeoMahesh Patel
Security nameLipocine Inc
Issue typecs
Sic code2834
Employees11
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address675 S Arapeen Dr Ste 202
StateUtah
CitySalt Lake City
Zip84108-1295
CountryUS
Phone18019947383

About Lipocine Inc

Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, has received tentative approval from the U.S. Food and Drug Administration (the 'FDA') for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. LPCN 1144, an oral prodrug of bioidentical testosterone, recently completed a proof-of-concept clinical study demonstrating the potential utility in the treatment of non-cirrhotic NASH. LPCN 1144 is currently being studied in a Phase 2 clinical study. TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a Phase 2 clinical evaluation when administered once daily or twice daily, TLANDO XR met the typical primary and secondary end points. LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the treatment of cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA.